Table 3.

The correlations between the overall survival and various clinicopathological factors

	Univariate analysis			Multivariate analysis
	Hazard ratio	95% CI	p-value	Hazard ratio	95% CI	p-value
Age (≥65 vs. < 65 years)	1.266	0.869–1.845	0.219
Gender (Female vs. Male)	1.300	0.895–1.888	0.169
Performance status (≥1 vs. 0)	1.847	1.098–3.106	0.021	1.501	0.767–2.936	0.236
Location of primary tumor (Right side vs. Left side)	1.985	1.273–3.094	0.002	2.441	1.427–4.175	0.001
Histological type (Poorly, Mucinous vs. Well, Moderately)	0.710	0.368–1.370	0.307
RAS status (Wild type vs. Mutant type)	1.697	1.095–2.628	0.018	1.416	0.902–2.222	0.131
Detection of unresectable tumor (Synchronous vs. Metachronous)	1.087	0.723–1.635	0.687
Number of organs affected by metastasis (≥2 vs. 1)	1.142	0.770–1.693	0.509
Peritoneal dissemination (Positive vs. Negative)	1.156	0.732–1.824	0.534
Molecular-targeted therapy (Absent vs. Present)	1.148	0.783–1.684	0.480
ALI (Low vs. High)	2.571	1.754–3.769	< 0.001	2.773	1.773–4.335	< 0.001

CI Confidence interval, ALI Advanced lung cancer inflammation index